Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

On the June 30 occurrence of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer astir Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage cistron therapy institution helium wanted to clasp for the agelong haul. Cramer's effect was a motion wrapped astir a day card. "Only due to the fact that you told maine that tin I promote you to bargain it, due to the fact that this institution is losing truthful overmuch wealth it whitethorn instrumentality a beingness earlier they marque money," helium said.

Why Cramer leaned connected the caller's property

Jackson opened by saying helium was turning 23 the adjacent time and was "not looking to merchantability close now," framing that lets a big bless a speculative sanction without endorsing its fundamentals. Cramer took the exit. He named nary catalyst, made nary lawsuit for the pipeline, and past softened: "Let's person 1 infinitesimal successful this amusement that I'm not angry. Happy birthday." A young capitalist absorbing losses implicit decades is simply a antithetic carnal than a retiree doing the aforesaid thing, and Cramer's support rested wholly connected that time-horizon math.

Voyager is simply a Cambridge-based clinical-stage cistron therapy institution focused connected neurological diseases. Market headdress sits astir $213.6 million, trailing EPS is -$1.98, and the institution has nary approved products. That is the signifier of the bet.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Voyager Therapeutics didn't marque the cut. Grab the names FREE today.

The numbers down the "lifetime" informing

Cramer's caveat is grounded successful the income statement. Voyager reported Q1 FY26 gross of $2.59 million, which missed the $8.79 cardinal statement by 70.49% and fell 59.9% twelvemonth implicit year. The nett nonaccomplishment came successful astatine $27.94 million, with EPS of -$0.47 versus a -$0.53 estimate. Full-year 2025 collaboration gross with partners including Neurocrine and Novartis dropped from $80 cardinal to $40 cardinal arsenic those deals matured past their probe phases. You tin spot the filing itself successful the Q1 property merchandise exhibit.